Payment overview · 2025
General Payments
$498.92
37 reported records · 11 companies
Healthcare provider profile · identity verified
Keith David Mcdaniel, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · WILLIAMSBURG, KY · NPI 1205454451
Verified facts
What the public records show
CMS Open Payments records show Keith David Mcdaniel, APRN received $498.92 in general payments during 2025 across 37 reported records.
ABBVIE INC. accounted for 28.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $142.88 | 28.6% | 16 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $140.26 | 28.1% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $46.66 | 9.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.62 | 8.5% | 3 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.79 | 5.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.40 | 4.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.55 | 3.9% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $16.76 | 3.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.25 | 3.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.15 | 2.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.60 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $498.92 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $140.26 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $124.30 | 15 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $124.30 | 15 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $46.66 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $42.62 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $28.36 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
71 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 306 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 277 | 50 |
| Fluconazole | Fluconazole | 162 | 65 |
| Ondansetron Odt | Ondansetron | 144 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 127 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 127 | 32 |
| Lisinopril | Lisinopril | 126 | 32 |
| Promethazine Hcl | Promethazine Hcl | 121 | 37 |
| Montelukast Sodium | Montelukast Sodium | 110 | 26 |
| Amoxicillin | Amoxicillin | 97 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 31 |
| Omeprazole | Omeprazole | 95 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 22 |
| Amlodipine Besylate | Amlodipine Besylate | 89 | 24 |
| Ibuprofen | Ibuprofen | 89 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 29 |
| Atorvastatin Calcium | Atorvastatin Calcium | 84 | 26 |
| Ventolin Hfa | Albuterol Sulfate | 83 | 22 |
| Prednisone | Prednisone | 82 | 51 |
| Tizanidine Hcl | Tizanidine Hcl | 76 | 26 |
| Mounjaro | Tirzepatide | 71 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 17 |
| Potassium Chloride | Potassium Chloride | 70 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 66 | 46 |
| Famotidine | Famotidine | 64 | 25 |
| Methylprednisolone | Methylprednisolone | 63 | 39 |
| Meloxicam | Meloxicam | 57 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | suppressed |
| Ozempic | Semaglutide | 50 | 11 |
| Linzess | Linaclotide | 49 | 11 |
| Metformin Hcl | Metformin Hcl | 48 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Furosemide | Furosemide | 46 | suppressed |
| Losartan Potassium | Losartan Potassium | 46 | 13 |
| Sertraline Hcl | Sertraline Hcl | 45 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 45 | 13 |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Nystatin | Nystatin | 42 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 42 | 11 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Ofloxacin | Ofloxacin | 40 | 24 |
| Trazodone Hcl | Trazodone Hcl | 40 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 36 | 11 |
| Mupirocin | Mupirocin | 36 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Cephalexin | Cephalexin | 33 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Simvastatin | Simvastatin | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 20 |
| Carvedilol | Carvedilol | 24 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 24 | 16 |
| Single Use Swab | Alcohol Antiseptic Pads | 24 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Eliquis | Apixaban | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 13 |
| Alprazolam | Alprazolam | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Cefdinir | Cefdinir | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 20 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 14 |
| Celecoxib | Celecoxib | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 17 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 17 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 14 |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $498.92 · 37 records | ABBVIE INC. | CAPLYTA, JOURNAVX, KISUNLA, LEQVIO, NURTEC ODT, PAXLOVID, QULIPTA, Qelbree, REXULTI, UBRELVY, VOQUEZNA, VRAYLAR, VYEPTI, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error